SANTA CRUZ, Calif., Sept. 20, 2011 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company's sshRNA platform.
SomaGenics, along with its collaborators at Tekmira Pharmaceuticals and Roche, presented the results in a poster entitled "Synthetic Short shRNAs are Potent Inhibitors of Hepatitis C Virus in HCV-Infected Chimeric Mice" at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society held September 8-10, 2011 in Copenhagen, Denmark.
"The demonstration of a strong antiviral effect in the chimeric human liver mouse model further reinforces our confidence in the therapeutic potential of our sshRNA platform. We are quite excited about the performance of SomaGenics' synthetic sshRNAs formulated with Tekmira's lipid nanoparticles (LNPs), which demonstrated reduction of circulating HCV load by more than two orders of magnitude. The results presented affirm the advantages of our approach to combine multiple sshRNA targeting otherwise 'undruggable' viral targets," said Dr. Brian Johnston, Chief Executive of SomaGenics.
Some conclusions of the scientific presentation:
|SOURCE SomaGenics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved